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Abstract
A mild synthetic method for N-formyl-Met-Leu-Phe-OH (1) is described. After Fmoc solid phase peptide synthesis, on-bead
formylation and HPLC purification, more than 30 mg of the fully 13C/15N-labelled tripeptide 1 could be isolated in a typical batch.
This peptide can be easily crystallised and is therefore well suited as a standard sample for setting up solid-state NMR experiments.
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Introduction
There appears to be a general lack of widely available and
standardised samples for setting up new solid-state NMR exper-
iments. Such a standard sample should show a small 13C and
15N linewidth and a short 1H T1 relaxation time. It should
contain a number of molecular groups with different chemical
shifts for setting up correlation spectra. The 13C/15N-labelled
tripeptide N-formyl-Met-Leu-Phe-OH (f-MLF-OH) (1) has
been shown in a number of solid-state NMR studies to fulfil
these criteria. It has been used in great detail to examine spin
dynamics in peptide and for distance measurements [1-9]. MLF
is a chemotactic peptide which plays an important role in anti-
body research [10].
Although this tripeptide was briefly commercially available in
the past, only one synthesis of f-MLF-OH (1) by solid phase
methods has been published so far [11]. Rigorous reaction
conditions (EtOH, reflux, 24–65 h) were required to couple the
first Boc-protected amino acid to the solid support (chloro-
methyl resin) and long reaction times (18 h) were necessary to
attach further building blocks to the growing peptide chain. TheBeilstein Journal of Organic Chemistry 2008, 4, No. 35.
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Scheme 1: Synthesis of f-MLF-OH (1). a) Fmoc-Phe-OH, MSNT, MeIm, over night. b) 1. piperidine, 30 min; 2. Fmoc-Leu-OH, DIC, HOBt*H2O, 3 h. c)
1. piperidine, 30 min; 2. Fmoc-Met-OH, DIC, HOBt*H2O, 3 h; 3. piperidine, 30 min. d) HCOOEt, over night. e) TFA, EDT, H2O, TIS (94 : 2.5 : 2.5 : 1),
4.5 h. All reactions were carried out at room temperature. Abbreviations: MSNT = 1-(mesitylene-2-sulphonyl)-3-nitro-1,2,4-triazole, MeIm = N-methyl-
imidazole, DIC = diisopropylcarbodiimide, HOBt = 1-hydroxybenzotriazole, TFA = trifluoroacetic acid, EDT = ethanedithiole, TIS = triisopropylsilane.
formylation of the N-terminus with formic acid/acetic anhyd-
ride was carried out after cleavage from the resin with liquid
hydrogen fluoride [11,12]. No experimental procedures were
given in all subsequent publications. In this work, we present
for the first time in detail an improved practical synthesis for




The synthesis of the MLF tripeptide started with the immobil-
isation of 13C/15N-labelled Fmoc-Phe-OH to the solid support
(Wang resin 2). This esterification step, leading to 3 quantitat-
ively, was performed by activating the COOH group with
MSNT under mild reaction conditions (Scheme 1) [13]. Full
conversion of the resin bound hydroxy groups could be demon-
strated by a colourimetric test with Dabcyl-COOH [14]. After
removal of Fmoc with piperidine, the 13C/15N-labelled
monomers Fmoc-Leu-OH and Fmoc-Met-OH were success-
ively coupled to the solid support with DIC/HOBt [15]. Quantit-
ative conversion in each reaction was monitored by the Kaiser
test [16,17]. The resulting tripeptide 4 was formylated under
mild conditions with 13C-labelled ethyl formate to obtain 5
[18]. The main advantage of using ethyl formate is the possib-
ility of re-isolation of the expensive 13C-labelled reagent for
further formylation reactions, due to the absence of activating
agents. To the best of our knowledge, formylation reactions of
N-termini with ethyl formate have never been reported before in
solid phase peptide synthesis. Other methods of formylation
were not tested, since they require elevated reaction temperat-
ures or acidic conditions [19,20], which might cause some
premature removal of the peptide from the resin. The final step
was the cleavage of f-MLF-OH (1) from the solid support with
TFA [21,22]. To prevent by-product formation from electro-
philic intermediates present in the cleavage process, EDT and
TIS were added as scavengers [23,24].
Conclusion
Compared to the solution phase synthesis of peptides, the solid
phase synthesis offers a simplified purification of the intermedi-
ates. With the improved synthetic protocol based on Fmoc
building blocks, where all reaction steps were carried out at
room temperature, we were able to obtain the per-13C/15N-
labelled formylated Met-Leu-Phe tripeptide as carboxylic acid
in acceptable yields [32.8 mg (23%) after HPLC purification].
Due to the selected reagents, i.e. MSNT for the esterification,
DIC/HOBt for the peptide coupling and ethyl formate for the
formylation, shorter reaction time and quantitative conversion
could be accomplished when compared to the previous protocol
from 1976 [11], where yields are not given. In contrast to theBeilstein Journal of Organic Chemistry 2008, 4, No. 35.
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Boc-strategy, the Fmoc-method for solid phase peptide
synthesis has the advantage of orthogonal conditions for the
removal of N-protective groups and the cleavage from the
Wang resin [25]. Unintentional release of the growing peptide
chain thus could be excluded. In addition, the use of liquid
hydrogen fluoride is no longer required.
Experimental
General: All reagents were obtained from commercial
suppliers and were used without further purification. HPLC
gradient: 0–5 min (0.1% TFA/MeCN 99:1), 5–20 min (0.1%
TFA/MeCN 99:1 to 30:70), 20–25 min (0.1% TFA/MeCN
30:70), 25–30 min (0.1% TFA/MeCN 30:70 to 99:1), 30–40
min (0.1% TFA/MeCN 99:1). ESI-MS: Fisons VG Plattform II.
NMR: Bruker AM 300 (1H: 300 MHz; 13C: 75.5 MHz).
Immobilisation of the first monomer: Wang resin (485 mg,
0.315 mmol, capacity: 0.65 mmol/g) was swelled under argon
with dry CH2Cl2 (1.5 mL) in an oven dried reaction vessel for
15 min. In a second dry vessel, 13C/15N-labelled Fmoc-Phe-OH
(250 mg, 0.63 mmol) was dissolved in dry CH2Cl2 (3 mL) and
MeIm (94 µL, 1.18 mmol). Afterwards MSNT (467 mg, 1.576
mmol) was added. The reaction mixture was shaken under
argon until MSNT had completely dissolved. The amino acid
solution was transferred via syringe to the resin and the suspen-
sion was flushed with argon. The sealed reaction vessel was
gently agitated over night.
The beads were transferred to a syringe with a filter and washed
with dry CH2Cl2 (5 ×). Some beads were dried in vacuo for the
following colourimetric test with Dabcyl-COOH for the detec-
tion of polymer-supported OH groups [14]. (See Supporting
Information File 1.)
Coupling of further building blocks: In case of quantitative
conversion, the resin was washed with N,N-dimethylformamide
(DMF, 5 ×) and treated three times (15 min, 10 min, 5 min)
with a piperidine solution (25% in DMF). Then the resin was
washed with N-methylpyrrolidone (NMP, 5 ×) and a solution of
13C/15N-labelled Fmoc-Leu-OH (250 mg, 0.69 mmol),
HOBt*H2O (145 mg, 0.945 mmol) and DIC (145 µL, 0.945
mmol) in NMP (2.5 mL) was aspirated into the syringe for the
next coupling step. After 3 h the resin was washed with NMP
(5 ×) and a few beads were tested for quantitative conversion by
the Kaiser test [16,17]. (See Supporting Information File 1.)
In case of a successful peptide extension, the Fmoc-protecting
group was removed with piperidine (25% in DMF). Afterwards,
the last coupling step was started by adding a solution of 13C/
15N-labelled Fmoc-Met-OH (250 mg, 0.66 mmol), HOBt*H2O
(145 mg, 0.945 mmol) and DIC (145 µL, 0.945 mmol) in NMP
(2.5 mL). In case of quantitative coupling (Kaiser test), the
Fmoc-protecting group was removed and the resin was washed
with DMF (5 ×) and CH2Cl2 (5 ×). The beads were dried in the
syringe under reduced pressure.
Formylation of the N-terminus: For the following formyla-
tion, 13C-labelled ethyl formate (2 mL) was aspirated and the
syringe was shaken over night at room temperature. The quant-
itative conversion was proved by the Kaiser test, after washing
the resin with CH2Cl2 (5 ×).
Cleavage of the peptide from the solid support: For a
successful cleavage, it is highly recommended to dry the beads
in vacuo for at least 3 h. The cleavage solution [TFA (1.88 mL),
H2O (50 µL), EDT (50 µL) and TIS (20 µL)] was added to the
syringe. After shaking (3 × 90 min), the liberated peptide was
filtered off into Millipore™ water. This solution was lyophil-
ised and the residue was purified by HPLC. Yield: 32.8 mg
(23%).
HPLC conditions: Preparative: Reprosil AQ, 250 × 20, 10 µm,
0.1% TFA/MeCN (100:60), 10 mL/min; analytical: gradient:
Reprosil AQ, 125 × 4.6 mm, 5 µm, 0.8 mL/min, tR = 21.08 min;
isocratic: Lichrospher RP8 (Merck), 125 × 4.0 mm, 5 µm, 0.1%
TFA/MeCN (66:34), 0.8 mL/min, tR = 5.07 min.
13C NMR (δ[ppm] 75.5 MHz, MeCN-d3): 173.5 (m, 1C), 172.6
(m, 1C), 171.8 (m, 1C), 162.8 (d, J = 12.8 Hz, 1C), 138.0 (m,
1C), 131.1-126.8 (m, 5C), 55.1-51.3 (m, 3C), 41.3 (t, J = 34.4
Hz, 1C), 37.8 (m, 1C), 32.4 (t, J = 35.5 Hz, 1C), 30.4 (m, 1C),
25.4 (m, 1C), 23.2 (m, 1C), 21.7 (m, 1C), 15.3 (s, 1C).
MS (ESI): m/z (%) = 460.3 (100.0) [M–H]–, 13C21H3115N3O5S
calcd. 461.26.
Supporting Information
Procedures for colourimetric resin tests (including synthesis
and analytical data of Dabcyl-COOH), crystallisation
protocol, ESI, 13C NMR and 13C/15N MAS-NMR spectra
of f-MLF-OH (1) are available in the Supporting
Information.
Supporting Information File 1
A practical synthesis of the 13C/15N-labelled tripeptide
N-Formyl-Met-Leu-Phe, useful as a reference in solid-state
NMR spectroscopy.
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